Ezetimibe 11 items

Trials, agents, guidance

• Trial TANDEMCompleted September 2024

Studies

• TANDEM: obicetrapib plus ezetimibe fixed-dose combination cuts LDL-C by 48.6% versus placebo in 407 high-risk patients (Lancet 2025)Lancet · May 2025 9
• Phase 2 trial: obicetrapib plus ezetimibe on top of high-intensity statins cuts LDL-C by 63.4%, with 87% of patients reaching under 55 mg/dL (J Clin Lipidol 2023)J Clin Lipidol · January 2023 8
• Network meta-analysis of 9,248 patients ranks obicetrapib plus ezetimibe plus statin best overall, obicetrapib plus statin safest among CETP-inhibitor combinations (J Cardiovasc Pharmacol 2026)J Cardiovasc Pharmacol · April 2026 7
• Meta-analysis of 3,512 patients: obicetrapib added to ezetimibe nearly doubles LDL-C lowering seen with obicetrapib alone, but adds nothing to statins (Cardiol Rev 2026)Cardiol Rev · June 2026 6
• Meta-analysis of 657 patients: obicetrapib combination therapy, especially with ezetimibe at 10mg, beats obicetrapib monotherapy for LDL-C lowering (Semergen 2026)Semergen · January 2026 6
• REMBRANDT trial design: 300 ASCVD patients to test whether obicetrapib plus ezetimibe shrinks coronary plaque on CT angiography (Am Heart J 2025)Am Heart J · July 2025 6
• Meta-analysis of nine RCTs in 3,706 patients: obicetrapib plus ezetimibe adds a further 17.8% LDL-C reduction over obicetrapib alone (J Clin Lipidol 2025)J Clin Lipidol · January 2025 6
• Ezetimibe lowers CETP mass by 20 percent in most type 2 diabetes patients, tracking with HDL subclass shifts (Endocr J 2012)Endocr J · January 2012 6
• Ezetimibe does not blunt the HDL-raising effect of dalcetrapib, and each drug leaves the other pharmacokinetics largely unchanged (Br J Clin Pharmacol 2010)Br J Clin Pharmacol · December 2010 5
• In CETP mice, obicetrapib plus ezetimibe on top of atorvastatin regresses established atherosclerosis by 44% via LDL-receptor-driven VLDL clearance (J Lipid Res 2026)J Lipid Res · March 2026 4